We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Culver City, California Saturday, March 1, 2025, 17:00 Hrs [IST] ...

The FDA granted RMAT designation to nogapendekin alfa and CAR-NK for reversing lymphopenia in patients with cancer, with ...

ImmunityBio shares advanced 17% to $3.34 after the company said the Food and Drug Administration awarded a regenerative medicine advanced therapy designation for Anktiva and CAR-NK for the reversal of ...

ImmunityBio (NASDAQ:IBRX) stock rose 10% Friday morning after the company said it has received Regenerative Medicine Advanced ...

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation for ANKTIVA ...

ImmunityBio, Inc.’s IBRX share price has surged by 15.03%, which has investors questioning if this is right time to sell.

GAAP Net Income of $3.6 millionGenerated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-yearDelivered full-year 2024 adjusted EBITDA of $8.6 millionGenerated ZYNRELEF® Q4 2024 Net ...

Gene's lead asset shows high complete response rates in BCG-unresponsive NMIBC patients. Click here to read why ENGN stock is ...

The US Food and Drug Administration (FDA) approved 126 innovator and biosimilar drugs in 2024, significantly lower than the ...

After a momentous 2024, Culver City-based ImmunityBio Inc., the immunotherapy company founded and majority-owned by ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.